The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 29, 2010

Filed:

Sep. 25, 2007
Applicants:

Angeline Ingrid Bartholomeusz, Carnegie, AU;

Stephen Alister Locarnini, East St. Kilda, AU;

Anna Ayres, West Brunswick, AU;

Danielle Colledge, Bundoora, AU;

Joseph Sasadeusz, Parkville, AU;

Peter William Angus, East Ivanhoe, AU;

William Sievert, Clayton, AU;

Inventors:

Angeline Ingrid Bartholomeusz, Carnegie, AU;

Stephen Alister Locarnini, East St. Kilda, AU;

Anna Ayres, West Brunswick, AU;

Danielle Colledge, Bundoora, AU;

Joseph Sasadeusz, Parkville, AU;

Peter William Angus, East Ivanhoe, AU;

William Sievert, Clayton, AU;

Assignees:

Melborne Health, Parkville, AU;

Austin Health, Heidelberg, AU;

Southern Health, Clayton, AU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/00 (2006.01); C12Q 1/68 (2006.01); C12Q 1/70 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.


Find Patent Forward Citations

Loading…